|
Vol. 9.35 – 16 September, 2020
|
|
|
|
|
|
Researchers demonstrated that metabolic reprogramming induced by mitochondrial fusion was rate-limiting for immortalization of tumor-initiating cells and triggered their irreversible dedication to tumorigenesis.
[Cell]
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
Scientists established regionally derived models of glioblastoma edge and core that retained their spatial identity in a cell autonomous manner.
[Nature Communications]
|
|
|
|
|
Researchers presented a novel approach to target and reduce the frequency of aldehyde dehydrogenase (ALDH)high CSCs by vaccination against ALDH.
[Nano Letters]
|
|
|
|
|
Investigators demonstrated the dual-targeted delivery and enhanced therapeutic effect of eHNP-A1-CD15-LDE225 via scavenger receptor class B type 1 and CD15 on brain sonic hedgehog subtype of medulloblastoma cells in vitro, ex vivo, and in vivo. [Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
Scientists found that the stress-like subpopulation of cancer cells was present from the early stages of tumorigenesis.
[Cell Systems]
|
|
|
|
|
When dynamically labeling breast cancer cells along cancer progression, investigators observed that the majority of circulating tumor cells (CTCs) clusters undergone hypoxia, while single CTCs were largely normoxic.
[Cell Reports]
|
|
|
|
|
Researchers presented a therapeutically relevant crosstalk between Hedgehog signaling and the glucocorticoid receptor pathway acting at the level of GLI1 transcription factor. [Oncogene]
|
|
|
|
|
The authors demonstrated that carnitine palmitoyltransferase I (CPT1A), a key enzyme controlling fatty acid oxidation, was upregulated in colon cancer cells upon exposure to adipocytes or fatty acids. [Cell Death & Disease]
|
|
|
|
|
Scientists identified a mechanism of radioresistance mediated by linc-RA1 (radioresistance-associated long intergenic noncoding RNA 1). Linc-RA1 was upregulated in radioresistant glioma cells and glioma tissue samples, compared with radiosensitive cells and nontumor tissues.
[Cell Death & Disease]
|
|
|
|
|
Investigators showed that prostate cancer stem-like cells also colonizing prostate-draining lymph nodes of transgenic adenocarcinoma of the mouse prostate mice overexpressed galectin 3. [Frontiers in Immunology]
|
|
|
|
|
Researchers hypothesized that tumor relapse after the selective targeting of CSCs was due to intermediate progenitor cells that maintained the tumor volume. In order to support this hypothesis, they implemented a mathematical model derived using pseudo-reactions representing the events of each cell subpopulation within the tumor. [Cancers]
|
|
|
|
|
Scientists clarified the potential involvement of long non-coding RNA SNGH3 in the acquisition of cisplatin resistance and stemness in gastric cancer.
[Cellular Oncology]
|
|
|
|
|
|
The authors describe key chromatin regulatory pathways disrupted in gliomas, delineating their physiological function and the current understanding of how their dysregulation may contribute to gliomagenesis.
[Cancer Cell]
|
|
|
|
|
Investigators provide a sketch of the inhibiting roles of current chloroquine analogues and antibiotic combination in CSC autophagy process and discuss the possibility that pre‐clinical and clinical potential therapeutic strategy for anticancer therapy.
[Journal of Cellular and Molecular Medicine]
|
|
|
|
|
The authors discuss the multifaceted contribution of microRNAs, long non-coding RNAs, and circular RNAs, as representative ncRNA classes, in sustaining the CSC-like traits, as well as the underlying molecular mechanisms of their action in various CSC types.
[International Journal of Molecular Sciences]
|
|
|
|
|
|
Ryvu Therapeutics announced that the first patient had been treated in Europe for the cohort expansion part of Phase II DIAMOND-01 clinical trial investigating SEL24/MEN1703, a first-in-class, oral dual PIM/FLT3 inhibitor, as single agent in acute myeloid leukemia.
[Ryvu Therapeutics]
|
|
|
|
|
Mateon Therapeutics announced that the FDA designated OXi4503 for treatment of acute myeloid leukemia due to genetic mutations that disproportionately affected pediatric patients as a drug for a “rare pediatric disease,” as defined in section 529(a)(3) of the Federal Food, Drug, and Cosmetic Act.
[Mateon Therapeutics]
|
|
|
|
|
|
|
|
|
The University of Georgia – Athens, Georgia, United States
|
|
|
|
|
Karolinska Institute – Solna, Sweden
|
|
|
|
|
Karolinska Institute – Solna, Sweden
|
|
|
|
|
Icahn School of Medicine at Mount Sinai – New York City, New York, United States
|
|
|
|
|
St. Anna Children’s Cancer Research Institute – Vienna, Austria
|
|
|
|
|